Carnovas 2.5


Carnovas 2.5


Stock Status:

In Stock

  • Choose your option

  • *Upload Prescription

    • (max file size 80 MB)



Nebivolol Hydrochloride



Nebivolol is shown in- Hypertension Treatment of basic hypertension Chronic heart disappointment (CHF) Treatment of steady gentle and direct constant heart disappointment in expansion to standard treatments in elderly patients.



Nebivolol could be a β adrenergic receptor blocking operator. Nebivolol hinders both β1 and β1 adrenergic receptors. Nebivolol needs natural sympathomimetic and film stabilizing action at restoratively significant concentrations. At clinically significant measurements, Nebivolol does not illustrate β1-adrenergic receptor barricade movement. Different metabolites, counting glucuronides, contribute to beta-blocking activity. Mode of Activity of Nebivolol included include: decreased heart rate decreased myocardia contractility diminution of tonic thoughtful outpouring to the outskirts from cerebral vasomotor centers suppression of renin movement and vasodilation and diminished fringe vascular resistance Pharmacokinetics: Nebivolol is metabolized by a number of courses, counting glucuronidation and hydroxylation by CYP2D6. The dynamic isomer (d-nebivolol) has an viable half-life of almost 12 hours in CYP2D6 broad metabolizers (most individuals), and 19 hours in destitute metabolizers and presentation to d-nebi


Dosage & Administration

The dose of Nebivolol should be individualized to the needs of the patient. For most patients, the recommended starting dose is 5 mg once daily, with or without food, as monotherapy or in combination with other agents. For patients requiring further reduction in blood pressure, the dose can be increased at 2-week intervals up to 40 mg. A more frequent dosing regimen is unlikely to be beneficial.



Nebivolol ought to be utilized with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium opponents (especially of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic specialists, such as disopyramide, are utilized concurrently. Both digitalis glycosides and β-blockers moderate atrioventricular conduction and diminish heart rate. Concomitant utilize can increment the hazard of bradycardia. Nebivolol ought to not be combined with other β-blockers. Patients accepting catecholamine-depleting drugs, such as reserpine or guanethidine, ought to be closely observed, since the included β-blocking activity of Nebivolol may deliver intemperate decrease of thoughtful movement. In patients who are accepting Nebivolol and clonidine, Nebivolol ought to be ceased for a few days some time recently the slow decreasing of clonidine. CYP2D6 Inhibitors: Utilize caution when Nebivolol is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, standard



Nebivolol is contraindicated in patients with serious bradycardia, heart piece more prominent than to begin with degree, cardiogenic stun, decompensated cardiac disappointment, wiped out sinus disorder (unless a lasting pacemaker is in put), or serious hepatic disability (Child-Pugh >B), and in patients who are easily affected to any component of this item.


Side Effects

Headache, nausea and bradycardia.


Pregnancy & Lactation

The nebivolol and bisoprolol organization deliver antagonistic impacts on fetal development and postnatal advancement, that limits their helpful utilize in females amid pregnancy.


Precautions & Warnings

Sudden Cessation of Treatment: Patients with coronary supply route malady treated with Nebivolol ought to be exhorted against sudden suspension of treatment. Serious worsening of angina and the event of myocardial localized necrosis and ventricular arrhythmias have been detailed in patients with coronary supply route illness taking after the sudden cessation of treatment with β-blockers. Myocardial dead tissue and ventricular arrhythmias may happen with or without going before worsening of the angina pectoris. Indeed patients without plain coronary course infection ought to be cautioned against interference or sudden suspension of treatment. As with other β-blockers, when suspension of Nebivolol is arranged, patients ought to be carefully watched and prompted to play down physical action. Nebivolol ought to be decreased over 1 to 2 weeks when conceivable. In the event that the angina declines or intense coronary lacking creates, it is suggested that Nebivolol be expeditiously reinstituted, at slightest temporarily.


Therapeutic Class

Beta-adrenoceptor blocking drugs, Beta-blockers


Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.


Pharmaceutical Name

Beximco Pharmaceuticals Ltd.